Results 111 to 120 of about 4,730,453 (227)

Fear of falling is associated with physical functioning, activity performance, and participation in individuals with multiple sclerosis

open access: yesPM&R, EarlyView.
Abstract Background Fear of falling (FoF) is a common concern in individuals with multiple sclerosis (MS). Understanding whether and how FoF affects activities and participation is crucial for developing effective rehabilitation programs in individuals with MS.
Libak Abou   +4 more
wiley   +1 more source

Potential of Ginkgo biloba Extract to Intervene in Chronic Inflammation‐Related Diseases

open access: yesPhytotherapy Research, EarlyView.
Chronic inflammation is a pathological mechanism underpinning many diseases. Ginkgo biloba extract (GBE) is well known for its anti‐inflammatory property. GBE and its active constituents have been shown to attenuate pro‐inflammatory cytokine production, suppress nuclear factor kappa B activation, restore redox homeostasis, and modulate disease‐relevant
Yipeng Lin   +7 more
wiley   +1 more source

Associations of cannabis use, tobacco use and co‐use with brain volume: A systematic review and meta‐analysis

open access: yesAddiction, EarlyView.
Abstract Background and aims Cannabis is the most widely used illicit drug worldwide and is often co‐used with tobacco, the leading cause of preventable death. Although cannabis and tobacco have distinct neurobiological actions, their associations with brain volumes are unclear.
Katherine Sawyer   +16 more
wiley   +1 more source

A patient with established primary progressive multiple sclerosis transitions to ‘secondary’ relapsing–remitting disease course following a fulminant demyelinating episode

open access: yes, 2011
Primary progressive multiple sclerosis (PPMS), relapsing remitting MS (RRMS) and acute disseminated encephalomyelitis (ADEM) are clinically and immunopathogenetically distinct phenotypes of inflammatory demyelinating disorders of the central nervous ...
Orhun H Kantarci   +11 more
core   +1 more source

Comparison of the Patients Suffering from Relapsing-Remitting Multiple Sclerosis with Healthy Individuals regarding Serum Selenium and Zinc Levels

open access: yesپزشکی بالینی ابن سینا, 2020
Background and Objective: Multiple sclerosis is an autoimmune disease of the central nervous system that causes demyelination and axonal damage. There are contradictory results regarding the effects of zinc and selenium on the prevention or reduction of ...
Ali Asghar Vahidinia   +3 more
doaj  

BrECADD in three days: Implementation of a condensed intensive first‐line regimen in Hodgkin lymphoma

open access: yesBritish Journal of Haematology, EarlyView.
BrECADD can be delivered over 3 days instead of four, reducing intravenous treatment days by 25% without compromising dose intensity. Among 30 patients with advanced‐stage Hodgkin lymphoma, no unexpected toxicity was observed; there were no early discontinuations, and 1‐year progression‐free and overall survival were both 100%.
Christian Peter Jaworek   +16 more
wiley   +1 more source

Beta-interferons in multiple sclerosis: A single center experience in India

open access: yesAnnals of Indian Academy of Neurology, 2010
Background: Indian-Asian multiple sclerosis behaves somewhat differently from Western disease. It is not known if the response to β-interferon is also different.
Gupta Salil, Varadarajulu R, Ganjoo R
doaj  

The immunological landscape of the area postrema in neuromyelitis optica spectrum disorders

open access: yesBrain Pathology, EarlyView.
Aquaporin‐4 antibody‐positive neuromyelitis spectrum disorder is characterized by large tissue destructive lesions in medulla, spinal cord, and optic nerves, with only partial recovery from clinical symptoms, and by lesions with very little tissue destruction and mostly complete recovery from clinical symptoms, as seen in the area postrema ...
Qian Yu   +11 more
wiley   +1 more source

Effect of BG-12 on contrast-enhanced lesions in patients with relapsing-remitting multiple sclerosis: subgroup analyses from the phase 2b study

open access: yes, 2011
Background: In a phase 2b study in patients with relapsing–remitting MS (RRMS), BG-12 240 mg three times daily significantly reduced the number of new gadolinium-enhanced (Gd+) lesions from weeks 12 to 24 (primary end point) by 69% compared with placebo.
Mefkure Eraksoy   +44 more
core   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy